Fusō Yakuhin Kogyo Co., Ltd. Securities Report - 103rd Period (2025/04/01 - 2026/03/31)

Fusō Yakuhin Kogyo Co., Ltd. Securities Report - 103rd Period (2025/04/01 - 2026/03/31)

Fusō Yakuhin Kogyo Co., Ltd. has published its 103rd Securities Report. This report details the performance and financial situation from April 1, 2025, to March 31, 2026.

The company's main business is the research, development, manufacturing, and sales of pharmaceuticals. We provide high-quality pharmaceuticals and contribute to the improvement of patients' quality of life. Our products are highly evaluated both domestically and internationally and are widely used in medical settings.

This report reveals the company's financial situation, performance analysis, and future strategic direction. It is an important document for understanding trends in the pharmaceutical industry and serves as a valuable information source for investors and stakeholders.

To achieve sustainable growth, we focus on research and development and promote innovation. We will continue our efforts to provide high-quality pharmaceuticals and contribute to the improvement of patients' quality of life.